Clinical Trial Update: The Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in Women [NA]

View source ↗

Summary

This clinical trial evaluates the efficacy and safety of FRD001 as an ultrasound contrast agent for malignant ovarian masses and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• FRD001

Snippet

Sponsor: Tongji Hospital | Conditions: Ovary Cancer | NA | Status: RECRUITING